Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Amino Acids

Dasatinib

Ketoconazole

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Clotrimazole

Miconazole

Antifungal Agents

Cytochrome P-450 Enzyme Inhibitors

Hormones

Hormone Antagonists

Cytochrome P-450 CYP3A Inhibitors

Tyrosine

Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.

Dasatinib + Ketoconazole

The purpose of Segment 1 of the study is to determine the effect of ketoconazole on dasatinib. The purpose of Segment 2 is to learn how dasatinib affects tumor growth in patients with advanced solid tumors.

Study of Dasatinib in Patients With Advanced Solid Tumors

Phase I Study to Evaluate the Effect of Ketoconazole on the Pharmacokinetics of Dasatinib and the Effect of Dasatinib on Pharmacodynamic Markers in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Dasatinib in Patients With Advanced Solid Tumors	NCT00162214	Tumors	Dasatinib + Ket...	18 Years -	Bristol-Myers Squibb
Study of Dasatinib in Patients With Advanced Solid Tumors	NCT00162214	Tumors	Dasatinib + Ket...	18 Years -	Bristol-Myers Squibb
Study of Dasatinib in Patients With Advanced Solid Tumors	NCT00162214	Tumors	Dasatinib + Ket...	18 Years -	Bristol-Myers Squibb
Study of Dasatinib in Patients With Advanced Solid Tumors	NCT00162214	Tumors	Dasatinib + Ket...	18 Years -	Bristol-Myers Squibb

Spots Global Cancer Trial Database for dasatinib + ketoconazole